- Home
- HOMB vs MRUS Comparison
HOMB vs MRUS Comparison
Compare HOMB & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOMB
- MRUS
- Stock Information
- Founded
- HOMB 1998
- MRUS 2003
- Country
- HOMB United States
- MRUS Netherlands
- Employees
- HOMB N/A
- MRUS N/A
- Industry
- HOMB Major Banks
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HOMB Finance
- MRUS Health Care
- Exchange
- HOMB Nasdaq
- MRUS Nasdaq
- Market Cap
- HOMB 5.0B
- MRUS 4.1B
- IPO Year
- HOMB 2006
- MRUS 2016
- Fundamental
- Price
- HOMB $29.48
- MRUS $54.74
- Analyst Decision
- HOMB Hold
- MRUS Strong Buy
- Analyst Count
- HOMB 5
- MRUS 13
- Target Price
- HOMB $31.00
- MRUS $88.54
- AVG Volume (30 Days)
- HOMB 1.0M
- MRUS 706.3K
- Earning Date
- HOMB 07-16-2025
- MRUS 07-31-2025
- Dividend Yield
- HOMB 2.66%
- MRUS N/A
- EPS Growth
- HOMB 8.29
- MRUS N/A
- EPS
- HOMB 2.09
- MRUS N/A
- Revenue
- HOMB $987,214,000.00
- MRUS $54,732,000.00
- Revenue This Year
- HOMB $11.25
- MRUS $68.08
- Revenue Next Year
- HOMB $2.78
- MRUS $0.09
- P/E Ratio
- HOMB $14.04
- MRUS N/A
- Revenue Growth
- HOMB 1.15
- MRUS 42.77
- 52 Week Low
- HOMB $24.22
- MRUS $33.19
- 52 Week High
- HOMB $32.91
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- HOMB 59.04
- MRUS 56.79
- Support Level
- HOMB $29.22
- MRUS $51.78
- Resistance Level
- HOMB $29.98
- MRUS $55.30
- Average True Range (ATR)
- HOMB 0.54
- MRUS 1.63
- MACD
- HOMB 0.12
- MRUS -0.11
- Stochastic Oscillator
- HOMB 77.92
- MRUS 84.09
About HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.